1 / 29

Improving Access to the NHS

Improving Access to the NHS. Chris Counsell R&D Manager University Hospital Birmingham. NHS R&D Forum Conference 10 May, 2006. Talk Outline. R&D Office Processes Sponsorship SSAs Commercial Studies R&D budget allocation Future Data. R&D Office. 2.5 wte personnel

charlotte
Download Presentation

Improving Access to the NHS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Improving Access to the NHS Chris Counsell R&D Manager University Hospital Birmingham NHS R&D Forum Conference 10 May, 2006

  2. Talk Outline • R&D Office • Processes • Sponsorship • SSAs • Commercial Studies • R&D budget allocation • Future • Data

  3. R&D Office • 2.5 wte personnel • R&D Director – 2 sessions • R&D Manager – 0.5 wte • R&D Administrator – 0.75 wte • Clinical Trials Officer – 1.0 wte • Research Governance Manager – 1.0 wte - post frozen • ~200 studies per year (+50 student)

  4. Database • In-house • ‘Management System’ not just Information system • Networked with offline copy • Triggers events • Warns against, and prevents, certain actions • Role specific features • Linked to MS Word – standard letters, MS Outlook – emails, Adobe Acrobat – electronic study files • Linked to other databases – publications, university income, • Picks out keywords in text to characterise study (e.g. CT-IMP, Gene Therapy, involves ionising radiation etc.)

  5. R&D Process – Principles • Study registration is the hook • No committee • Not role of R&D office to judge research • Role to coordinate discussion and agreement between PI and relevant services • Not do PI’s job – i.e. do not ‘champion’ the research • Vast majority of research ok – process needs to be able to identify and deal with the few problems • Fit as far as possible with existing processes and procedures within Trust

  6. Submission Information • Minimum • Protocol (+ request to start processing) • Provisional approval • Participant Information sheet(s) + sample consent forms • Ethics Parts A,B (& C) • Written evidence of sponsorship (or request for UHB to act as sponsor) • NHS R&D Form (not a requirement) • Full approval • Ethics approval • Regulatory approval

  7. Principal Investigator Criteria • For any study that involves intervention in care of patient. PI must: • hold substantive or honorary contract with Trust • be of consultant status or equivalent From October 2006 • have evidence of recent accredited GCP training

  8. Approval Processes • 3 different routes • Normal • Most studies, requires local principal investigator (PI) • ‘no objection’ • Has no local PI; declared SSA exempt; makes no use of Trust resources beyond usual care • Student • Approved by student sub-committee of South Birmingham REC

  9. Full approval requirements • Sufficient information to register with NRR (non-commercial) • Principal Investigator agreement (or signed NHS R&D Form) • Clinical Director approval (or signed on NHS R&D Form) • No service objections • Sponsorship • Indemnity and contract finalised (for commercial studies) • IRMER 8 form (ionising radiation) • GMSC approved (gene therapy studies) • Treatment continuation (CTIMP) If all met before ethics approval – issue ‘provisional’ approval (and sign contracts) If ethics approved but conditions not met – issue ‘hold’ approval (do not sign contracts) • Ethics approval • MHRA approval (medicines trial) • Confirm full Trust approval

  10. ‘No Objection’ Requirements • Sufficient information to register with NRR (non-commercial) • No objection from relevant clinical/service lead • Sponsor identified • Study approved by REC and declared SSA-exempt, or does not require REC approval Condition of approval is that researchers only have limited access to Trust resources

  11. Student Studies • Approved by student sub-committee of South Birmingham REC • If research supervisor does not hold contract with Trust, must appoint clinical supervisor who does • Clinical and research supervisors sign acceptance of their roles • Research supervisor accepts sponsorship on behalf of University

  12. Full Approval PI R&D Office Clinical Director Pharmacy Service Leads Regulatory checks Dialogue Information approval required/not required

  13. Student R&D Office Student Research Supervisor Service Leads Clinical Supervisor Regulatory checks

  14. ‘no objection’ R&D Office CI Service /Dept. Head Regulatory checks

  15. Process Status 2 months +1 month Registered Abandoned Processing 2 months +1 month Withdraw Provisional Reject Provisional Approval 2 months Full Approval

  16. Delays • Clinical Director signature • IRMER • PI not responding / returning documents • Sponsorship • Contract (particularly if not standard mCTA) • Costings

  17. Fate of Studies Registered in 2005 Student 39 Registered 239 Abandoned 10 (3 on-going) Other 14 1 not UHBT 1 reject by ethics 12 abandoned by PI/sponsor Abandoned 10 Processing 173 Other 10 2 not UHBT 8 abandoned by PI/sponsor Reinstated 5 (20 on-going) ‘No Objection’ 10 Provisional approval 66 Withdraw provisional 22 Abandoned 5 (6 on-going) (3 on-going) Full approval 62 Confirmed 38 Approved 14

  18. Trust Sponsorship • PI must complete sponsor request form • Provisional agreement to act as sponsor dependent on ethics/regulatory approval plus satisfactory funding (if externally funded) • UHB agreed to act as sponsor for 30% of studies registered in 2005. • Of which 90% are single-centre, 5 CTIMPs • Requested ethics to accept UHB sponsorship only if application contains letter from R&D office – not always followed • Site agreements – mainly for multicentre CTIMPs • Chief Investigator agreements – from May 2006

  19. Site Specific Assessments (SSAs) • Part Cs submitted to South Birmingham REC • Forwarded to UHB R&D • SSA committee • SBREC Chair + 1 other • R&D Director (SSA Chair), R&D Manager + 1 other • Assessments all by email – return deadline • Require at least 2 responses to Chair for final decision • R&D admin emails decision to SBREC • SBREC updates ethics database

  20. SSAs • 164 SSAs Since March 2005 • Median response time 10 working days • Objections raised on 14 studies • Suitability of PI • Suitability of facilities • Use of translation services • Queries raised with main REC

  21. Commercial Studies • Contracts and costings handled through R&D Office • Follow NHS R&D Forum costing guidance • Clinical Trials Officer uses protocol and visit grid to draw up first-pass costing • Circulated to all relevant service leads + PI for confirmation • PI agrees final budget with Sponsor (either directly or via R&D) which must cover agreed service costs • Service leads + PI all sign agreements for internal transfer of funds

  22. Commercial cont. • All funds paid into named Research Accounts (rules similar to charity accounts – including budget roll-overs) • Internal transfers to service departments • R&D Office Start up fee + 10% of per patient fee • Expect payments on invoices only (PIs learnt the hard way why – money lost in finance)

  23. Commercial contracts • Expect sponsors to use model CTA • Pharmacy now included in overall CTA (but can invoice separately) • If use University facilities, required to insert additional clause referencing sub-agreement • University Full Economic Costing significant increase in costs (some trials lost)

  24. Commercial Issues • Sponsors requiring unjustified changes to model CTA • CRO/Sponsor not communicating well • CRA trying to sort everything out independently of R&D • Changing contact at sponsor/CRO • Playing PI against R&D

  25. NHS R&D Support Funding internal allocation • All projects given a ‘weight’ – minimal, low, standard, high – dependent on strategic factors, not numbers of patients. • R&D Budget 1 allocation divided among clinical departments based on total relative weighting of previous year’s studies • Finance ‘cascade’ model determines allocations to all service departments • R&D budget line at high level only (Divisions and Groups) • Departments not required to reconcile R&D cost to R&D income

  26. Future • Web-based application process • Better link to other Trust & University databases (HR, Finance) • Link with external systems (Ethics, Funders, Regulators, Clinical Trials Registers etc.) • Paperless processing

  27. Post approval • Audit • Annual reports • Adverse event reporting • Amendments

  28. Study Numbers

  29. Approval Times

More Related